News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,335 Results
Type
Article (14136)
Company Profile (282)
Press Release (250917)
Section
Business (79471)
Career Advice (153)
Deals (13221)
Drug Delivery (35)
Drug Development (50414)
Employer Resources (31)
FDA (5708)
Job Trends (5127)
News (144324)
Policy (10027)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (907)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21616)
ALS (54)
Alzheimer's disease (807)
Antibody-drug conjugate (ADC) (79)
Approvals (5714)
Artificial intelligence (100)
Autoimmune disease (7)
Automation (5)
Bankruptcy (102)
Best Places to Work (4560)
BIOSECURE Act (5)
Biosimilars (35)
Biotechnology (232)
Bladder cancer (40)
Brain cancer (19)
Breast cancer (132)
Cancer (1174)
Cardiovascular disease (92)
Career advice (132)
Career pathing (2)
CAR-T (101)
Cell therapy (291)
Cervical cancer (5)
Clinical research (40671)
Collaboration (462)
Compensation (196)
Complete response letters (13)
COVID-19 (1029)
CRISPR (33)
C-suite (129)
Cystic fibrosis (75)
Data (1212)
Denatured (11)
Depression (27)
Diabetes (112)
Diagnostics (1283)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (74)
Drug pricing (27)
Drug shortages (3)
Duchenne muscular dystrophy (64)
Earnings (29389)
Editorial (16)
Employer branding (4)
Employer resources (29)
Events (47887)
Executive appointments (377)
FDA (6262)
Featured Employer (34)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (432)
Gene editing (80)
Generative AI (9)
Gene therapy (210)
GLP-1 (341)
Government (1074)
Grass and pollen (2)
Guidances (17)
Healthcare (6585)
Huntington's disease (21)
IgA nephropathy (18)
Immunology and inflammation (71)
Indications (16)
Infectious disease (1083)
Inflammatory bowel disease (109)
Inflation Reduction Act (8)
Influenza (16)
Intellectual property (51)
Interviews (17)
IPO (7255)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (6)
Labor market (4)
Layoffs (198)
Leadership (2)
Legal (1385)
Liver cancer (29)
Lung cancer (168)
Lymphoma (77)
Machine learning (1)
Management (7)
Manufacturing (107)
MASH (46)
Medical device (2584)
Medtech (2585)
Mergers & acquisitions (6219)
Metabolic disorders (334)
Multiple sclerosis (46)
NASH (13)
Neurodegenerative disease (53)
Neuropsychiatric disorders (22)
Neuroscience (1144)
NextGen: Class of 2025 (2014)
Non-profit (852)
Northern California (1415)
Now hiring (21)
Obesity (173)
Opinion (98)
Ovarian cancer (50)
Pain (38)
Pancreatic cancer (48)
Parkinson's disease (94)
Partnered (6)
Patents (98)
Patient recruitment (56)
Peanut (35)
People (25414)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14356)
Phase II (18922)
Phase III (11956)
Pipeline (575)
Podcasts (42)
Policy (33)
Postmarket research (852)
Preclinical (6014)
Press Release (30)
Prostate cancer (49)
Psychedelics (35)
Radiopharmaceuticals (210)
Rare diseases (262)
Real estate (1414)
Recruiting (12)
Regulatory (8496)
Reports (14)
Research institute (935)
Resumes & cover letters (17)
Rett syndrome (3)
RNA editing (1)
RSV (10)
Schizophrenia (52)
Series A (85)
Series B (51)
Service/supplier (1)
Sickle cell disease (37)
Southern California (1256)
Special edition (10)
Sponsored (11)
Startups (1969)
State (1)
Stomach cancer (4)
Supply chain (17)
The Weekly (31)
United States (11196)
Vaccines (195)
Venture capitalists (27)
Webinars (7)
Weight loss (97)
Women's health (14)
Worklife (2)
Date
Last 7 days (395)
Last 30 days (1605)
Last 365 days (20179)
2025 (3510)
2024 (20552)
2023 (22415)
2022 (26823)
2021 (27805)
2020 (23356)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (37)
Alaska (2)
Arizona (50)
Arkansas (5)
Asia (17142)
Australia (2902)
California (3231)
Canada (997)
China (290)
Colorado (125)
Connecticut (136)
Delaware (78)
Europe (36868)
Florida (376)
Georgia (95)
Idaho (16)
Illinois (200)
India (6)
Indiana (79)
Iowa (1)
Japan (63)
Kansas (58)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (424)
Massachusetts (2564)
Michigan (68)
Minnesota (124)
Mississippi (1)
Missouri (22)
Montana (14)
Nebraska (4)
Nevada (14)
New Hampshire (13)
New Jersey (811)
New Mexico (11)
New York (890)
North Carolina (497)
North Dakota (4)
Northern California (1415)
Ohio (102)
Oklahoma (8)
Oregon (21)
Pennsylvania (608)
Puerto Rico (1)
Rhode Island (13)
South America (207)
South Carolina (3)
Southern California (1256)
Tennessee (24)
Texas (365)
Utah (45)
Virginia (65)
Washington D.C. (27)
Washington State (302)
Wisconsin (13)
265,335 Results for "dianthus therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Dianthus Therapeutics to Participate in Two Upcoming March 2025 Investor Conferences
February 27, 2025
·
1 min read
Press Releases
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences
January 30, 2025
·
1 min read
Press Releases
Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
January 9, 2025
·
1 min read
Press Releases
Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors
March 5, 2025
·
7 min read
Press Releases
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
November 5, 2024
·
1 min read
Genetown
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
Dianthus Therapeutics, Inc. today announced its participation in the Jefferies Global Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Thursday, June 6, 2024 at 1:30 p.m. ET in New York.
May 30, 2024
·
4 min read
Genetown
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
Dianthus Therapeutics, Inc. reported financial results for the first quarter ending March 31, 2024, and provided an update on recent business achievements.
May 9, 2024
·
10 min read
Genetown
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, announced its participation in the Bank of America Securities 2024 Health Care Conference.
May 8, 2024
·
4 min read
Press Releases
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
November 8, 2024
·
12 min read
Drug Development
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)
Dianthus Therapeutics, Inc. announced U.S. Food and Drug Administration clearance of its Phase 2 Investigational New Drug application for the MoMeNtum trial of DNTH103 in patients with Multifocal Motor Neuropathy.
June 12, 2024
·
6 min read
1 of 26,534
Next
